Moteur de recherche d’entreprises européennes
Financement de l’UE (3 768 606 €) : Réseau européen de formation pour diagnostiquer, comprendre et traiter la maladie de Stargardt, une maladie héréditaire fréquente de cécité Hor 01/10/2018 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Réseau européen de formation pour diagnostiquer, comprendre et traiter la maladie de Stargardt, une maladie héréditaire fréquente de cécité
StarT will create an interdisciplinary and intersectorial European training network focusing on different aspects of autosomal recessive Stargardt disease (STGD1), a frequent inherited blinding disorder that affects an estimated 925,000 persons worldwide. StarT research aims to uncover the regulation of its disease gene ABCA4 and its missing heritability, in order to develop novel treatments. StarT training will give young researchers unparalleled training opportunities in outstanding vision research groups with unique expertise in omics technologies, bio-informatics, stem cell biology, animal models of disease, and therapeutics, providing each ESR with the necessary competences in state-of-the-art academic and industrial research. STGD1 is due to ABCA4 mutations, however up to 35% of STGD1 cases carries one or no ABCA4 coding mutation. New unconventional classes of ABCA4 mutations were recently discovered by us, the significance of which largely remains elusive. In order to understand the mechanisms triggered by these missing ABCA4 mutations and to design new therapies for STGD1 cases, challenging research questions will be addressed by the integration of unique skills from this network. Early-Stage Researchers will perform cutting edge research using innovative and interdisciplinary approaches: (functional) genomics and transcriptomics, bio-informatics, CRISPR/Cas9 genome editing, generation of stem cell and animal disease models and design of new treatments. The training objectives will be met through academic and industrial training-by-research via individual research projects, secondments, and network-wide training sessions.
| 20MED Therapeutics B.V. | ? |
| Agencia Estatal Consejo Superior de Investigaciones Cientificas | 250 905 € |
| Eberhard Karls Universitaet Tuebingen | 252 788 € |
| Fondazione Telethon ETS | 522 999 € |
| Newcells Biotech Ltd. | 303 173 € |
| Proqr Therapeutics N.V. | 265 620 € |
| Stichting Radboud Universitair Medisch Centrum | 291 223 € |
| Stichting Radboud Universiteit | 231 908 € |
| The Provost, Fellows Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near Dublin | 274 684 € |
| Universiteit Gent | 768 960 € |
| University College London | 303 173 € |
| University of Leeds | 303 173 € |
https://cordis.europa.eu/project/id/813490
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : 20MED Therapeutics B.V., Barchem, Pays-Bas.